Literature DB >> 28757404

Intermediate dose-volume parameters and the development of late rectal toxicity after MRI-guided brachytherapy for locally advanced cervix cancer.

Reem Ujaimi1, Michael Milosevic2, Anthony Fyles2, Akbar Beiki-Ardakani1, Marco Carlone1, Haiyan Jiang3, Patricia Lindsay2, Jason Xie1, Rachel Gerber1, Jennifer Croke2, Julia Skliarenko1, Wilfred Levin2, Kathy Han4.   

Abstract

PURPOSE: The dose delivered to the most exposed 2 cm3 [Formula: see text] of the rectum and bladder is predictive of late rectal and bladder toxicity in cervix cancer patients. We investigated the predictive value of intermediate doses to the rectum and bladder for late rectal/bladder toxicity after MRI-guided brachytherapy for patients with locally advanced cervix cancer. METHODS AND MATERIALS: Toxicity was prospectively graded using Common Toxicity Criteria for Adverse Events v4.0 and retrospectively verified for women with Stage IB-IVA cervix cancer treated consecutively with MRI-guided brachytherapy between 2008 and 2013. The minimum equivalent dose in 2 Gy fractions delivered to 0.1, 1, 2, 5, and 10 cm3 of the rectum and bladder and the absolute volume of the rectum receiving 55, 60, 65, 70, and 75 Gy3 (V55-75) were collected. The association between dose-volume parameters and Grade 2+ rectal/bladder toxicity was examined using logistic regression.
RESULTS: With a median followup of 44 months, cumulative incidences of Grade 2+ rectal and bladder toxicity among the 106 patients were 29% and 15% at 3 years, respectively. All the dose-volume parameters were significantly associated with late Grade 2+ rectal and bladder toxicity (p < 0.05), except for bladder [Formula: see text] . On multivariable logistic regression, both [Formula: see text]  > 70 Gy3 and V55 > 11 cm3 (p < 0.05) were predictive of late Grade 2+ rectal toxicity, with improved model fitting and higher area under the curve compared with the model with [Formula: see text]  > 70 Gy3 alone.
CONCLUSIONS: In this study, V55 was predictive of late Grade 2+ rectal toxicity. Adding V55 to  [Formula: see text] improved prediction accuracy.
Copyright © 2017 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bladder; Cervix cancer; Dosimetric parameter; MRI-guided brachytherapy; Rectum; Toxicity

Mesh:

Year:  2017        PMID: 28757404     DOI: 10.1016/j.brachy.2017.06.007

Source DB:  PubMed          Journal:  Brachytherapy        ISSN: 1538-4721            Impact factor:   2.362


  3 in total

Review 1.  The EMBRACE II study: The outcome and prospect of two decades of evolution within the GEC-ESTRO GYN working group and the EMBRACE studies.

Authors:  Richard Pötter; Kari Tanderup; Christian Kirisits; Astrid de Leeuw; Kathrin Kirchheiner; Remi Nout; Li Tee Tan; Christine Haie-Meder; Umesh Mahantshetty; Barbara Segedin; Peter Hoskin; Kjersti Bruheim; Bhavana Rai; Fleur Huang; Erik Van Limbergen; Max Schmid; Nicole Nesvacil; Alina Sturdza; Lars Fokdal; Nina Boje Kibsgaard Jensen; Dietmar Georg; Marianne Assenholt; Yvette Seppenwoolde; Christel Nomden; Israel Fortin; Supriya Chopra; Uulke van der Heide; Tamara Rumpold; Jacob Christian Lindegaard; Ina Jürgenliemk-Schulz
Journal:  Clin Transl Radiat Oncol       Date:  2018-01-11

2.  Role of non-absorbable oral antibiotics in bowel preparation for intracavitary brachytherapy: effects of rifaximin on rectal dosimetric parameters during vaginal cuff brachytherapy.

Authors:  Sasan Razmjoo; Ali Bagheri; Hodjatollah Shahbazian; Seyed-Mohammad Hosseini; Faezeh Ebrahimian-Tabrizi
Journal:  J Contemp Brachytherapy       Date:  2021-08-24

Review 3.  Prediction models for brachytherapy-induced rectal toxicity in patients with locally advanced pelvic cancers: a systematic review.

Authors:  Fariba Tohidinezhad; Yves Willems; Maaike Berbee; Evert Van Limbergen; Frank Verhaegen; Andre Dekker; Alberto Traverso
Journal:  J Contemp Brachytherapy       Date:  2022-08-31
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.